OM202JP Clinical Study of KNP2002

A Phase II Clinical Study of KNP2002 Ointment in Patients With Common Warts (OM202JA)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05896215

Enrollment

159

Registered

2023-06-09

Start date

2023-06-12

Completion date

2024-07-27

Last updated

2024-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Common Wart

Keywords

Common Wart

Brief summary

The goal of this clinical trial is to evaluate safety and efficacy of KNP2002 in patients with common warts aged 15 to 50 years old.

Interventions

DRUGKNP2002

Dairy topical administration for 12 weeks

DRUGPlacebo of KNP2002

Dairy topical administration for 12 weeks

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

15 Years to 49 Years

Healthy volunteers

Inclusion criteria

* Subjects aged 15 to 49 years old * Subjects with common warts on the upper or lower limb * Subjects who agree to contraception from obtaining consent to 4 weeks after the end of administration * Subjects who have given their voluntary written consent to participate in this clinical trial

Exclusion criteria

* Subjects with 5 or more warts on the upper or lower limbs * Subjects who are scheduled to undergo treatment such as physical therapy or chemotherapy for warts * Subjects with a history of allergy to topical skin preparations * Subjects with a history of malignant tumor within 5 years before administration of study drug * Subjects with any of the following diseases: Malignant tumor; Serious heart disease; Poorly controlled diabetes/hypertension * Women who are pregnant, may become pregnant, or are breastfeeding

Design outcomes

Primary

Measure	Time frame	Description
Change in wart area	At 16 weeks after starting administration	Percent change in wart area from baseline

Secondary

Measure	Time frame	Description
Change in wart area over time	At 4, 8, 12, and 16 weeks after starting administration	Percent change in wart area from baseline
Wart improvement rate	At 4, 8, 12, and 16 weeks after starting administration	Wart improvement rate categorized by rate of change in wart area
Wart disappearance rate	Up to 16 weeks after starting administration	Proportion of patients with warts disappearing

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026